BioMarin (BMRN)
Develops rare-disease medicines across enzyme therapies, metabolic disorders, and skeletal conditions.
$62.14
vs last close−1.23 (−1.94%)
Something off on this page? Send us feedback.
Next report
Oct 26, 26
in 33 days
EPS estimate
$1.34
Revenue estimate
$1.02B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported$0.64$0.97$1.23−$0.16−$0.24$0.76$1.20Pending
Estimate$0.54$0.71$0.86−$0.15$0.17$0.78$0.95$1.34
Surprise+18.5%+35.9%+42.9%−6.7%−241.7%−2.6%+26.7%—
RevenueReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported$747.0M$745.1M$825.0M$776.1M$874.6M$766.0M$989.7MPending
Estimate$712.3M$738.7M$761.9M$777.5M$833.7M$752.5M$932.0M$1.02B
Surprise+4.9%+0.9%+8.3%−0.2%+4.9%+1.8%+6.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | $1.89 | — | — |
| Sep 2027 | $1.70 | — | — |
| Jun 2027 | $1.59 | — | — |
| Mar 2027 | $1.44 | — | — |
| Dec 2026 | $1.75 | — | — |
| Oct 2026 | $1.34 | — | — |
| Aug 2026 | $0.95 | $1.20 | +26.7% |
| May 2026 | $0.78 | $0.76 | −2.6% |
| Feb 2026 | $0.17 | −$0.24 | −241.7% |
| Oct 2025 | −$0.15 | −$0.16 | −6.7% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Aug 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $1.15B | — | — | — |
| Sep 2028 | $0.00 | — | — | $992.9M | — | — | — |
| Jun 2028 | $0.00 | — | — | $989.7M | — | — | — |
| Mar 2028 | $0.00 | — | — | $766.2M | — | — | — |
| Dec 2027 | $1.89 | — | — | $1.16B | — | — | — |
| Sep 2027 | $1.70 | — | — | $1.13B | — | — | — |
| Jun 2027 | $1.59 | — | — | $1.10B | — | — | — |
| Mar 2027 | $1.44 | — | — | $1.04B | — | — | — |
| Dec 2026 | $1.75 | — | — | $1.13B | — | — | — |
| Oct 26, 2026 | $1.34 | — | — | $1.02B | — | — | — |
| Aug 6, 2026 | $0.95 | $1.20 | +26.7% | $932.0M | $989.7M | +6.2% | +3.8% |
| May 4, 2026 | $0.78 | $0.76 | −2.6% | $752.5M | $766.0M | +1.8% | −4.0% |
| Feb 23, 2026 | $0.17 | −$0.24 | −241.7% | $833.7M | $874.6M | +4.9% | −0.5% |
| Oct 27, 2025 | −$0.15 | −$0.16 | −6.7% | $777.5M | $776.1M | −0.2% | +1.6% |
| Aug 4, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 19, 2025 | |||||||
| Oct 29, 2024 | |||||||
| Aug 5, 2024 | |||||||
| Apr 24, 2024 | |||||||
| Feb 22, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Jul 31, 2023 | |||||||
| Apr 26, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Oct 26, 2022 | |||||||
| Aug 3, 2022 | |||||||
| Apr 27, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Oct 27, 2021 | |||||||
| Jul 28, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 4, 2020 | |||||||
| Apr 29, 2020 | |||||||
| Feb 26, 2020 | |||||||
| Oct 23, 2019 | |||||||
| Aug 1, 2019 | |||||||
| Apr 25, 2019 | |||||||
| Feb 21, 2019 | |||||||
| Oct 25, 2018 | |||||||
| Aug 2, 2018 | |||||||
| Apr 25, 2018 | |||||||
| Feb 22, 2018 | |||||||
| Oct 26, 2017 | |||||||
| Aug 2, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 23, 2017 | |||||||
| Oct 27, 2016 | |||||||
| Aug 4, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Oct 29, 2015 | |||||||
| Aug 3, 2015 |